The collaboration with Bayer, a major player in the pharmaceutical industry, not only validates Evotec's technology and approach to precision cardiology but also could lead to significant advancements in CVD treatments. This partnership is likely to be viewed positively by investors, as it represents a strategic move into a critical healthcare segment with a high unmet need, potentially leading to future revenue streams for Evotec.